Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors

Autor: Chunwei Xu, Bin Lian, Juanjuan Ou, Qian Wang, Wenxian Wang, Ke Wang, Dong Wang, Zhengbo Song, Aijun Liu, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Xiuyu Cai, Anwen Liu, Wen Li, Lili Mao, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Yu Chen, Jingping Yuan, Feng Wang, Zhansheng Jiang, Gen Lin, Long Huang, Xingxiang Pu, Rongbo Lin, Weifeng Liu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Junli Xue, Hui Guo, Qian Chu, Rui Meng, Jingxun Wu, Rui Zhang, Jin Zhou, Zhengfei Zhu, Yongheng Li, Hong Qiu, Fan Xia, Yuanyuan Lu, Xiaofeng Chen, Rui Ge, Enyong Dai, Yu Han, Weiwei Pan, Fei Pang, Jintao Huang, Kai Wang, Fan Wu, Bingwei Xu, Liping Wang, Youcai Zhu, Li Lin, Yanru Xie, Xinqing Lin, Jing Cai, Ling Xu, Jisheng Li, Xiaodong Jiao, Kainan Li, Jia Wei, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jianhui Huang, Yue Feng, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Zhaofeng Wang, Yue Hao, Zhen Wang, Bin Wan, Donglai Lv, Zhanqiang Zhai, Shengjie Yang, Jing Kang, Jiatao Zhang, Chao Zhang, Lin Shi, Yina Wang, Bihui Li, Zhang Zhang, Zhongwu Li, Zhefeng Liu, Nong Yang, Lin Wu, Huijuan Wang, Gu Jin, Guansong Wang, Jiandong Wang, Meiyu Fang, Yong Fang, Yuan Li, Xiaojia Wang, Jing Chen, Yiping Zhang, Xixu Zhu, Yi Shen, Shenglin Ma, Biyun Wang, Lu Si, Yuanzhi Lu, Ziming Li, Wenfeng Fang, Yong Song

Publikováno v: Global Medical Genetics, Vol 11, Iss 04, Pp 330-343 (2024)

The fibroblast growth factor receptor (FGFR) is a crucial receptor tyrosine kinase involved in essential biological processes, including growth, development, and tissue repair. However, FGFR gene mutations, including amplification, fusion, and mutati

Externí odkaz: https://doaj.org/article/d6d893b96da4470f8696347abc7c0079

Biological and clinical characteristics of non-small cell lung cancer non-specific subtype

Autor: Xiaohong Xie, Chen Zeng, Fei Wang, Guihuan Qiu, Ziyao Chen, Ting Liu, Xinqing Lin, Zhanhong Xie, Yinyin Qin, Yansheng Wang, Xiaodong Ma, Ming Liu, Chengzhi Zhou

Publikováno v: Heliyon, Vol 10, Iss 21, Pp e40092- (2024)

Background: Non-small cell lung cancer-not otherwise specified (NSCLC-NOS) is a rare subtype of NSCLC that cannot be classified specifically based on morphology and/or special staining. This study aimed to explore the clinical features, biological an

Externí odkaz: https://doaj.org/article/7b0b1c85e28f41b39f0f4f562ade3d73

The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial

Autor: Bo Cheng, Caichen Li, Jianfu Li, Longlong Gong, Peng Liang, Ying Chen, Shuting Zhan, Shan Xiong, Ran Zhong, Hengrui Liang, Yi Feng, Runchen Wang, Haixuan Wang, Hongbo Zheng, Jun Liu, Chengzhi Zhou, Wenlong Shao, Yuan Qiu, Jiancong Sun, Zhanhong Xie, Zhu Liang, Chenglin Yang, Xiuyu Cai, Chunxia Su, Wei Wang, Jianxing He, Wenhua Liang

Publikováno v: Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-13 (2024)

Abstract Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) protein significantly improve survival in patients with advanced non-small-cell lung cancer (NSCLC), but its impact on early-stage ground-glass opacity (GGO) lesions r

Externí odkaz: https://doaj.org/article/4d3035096197434f92f7d17580465bb5

A Nomogram for Predicting Cancer‐Specific Survival in Young Patients With Advanced Lung Cancer Based on Competing Risk Model

Autor: Jiaxin Li, Bolin Pan, Qiying Huang, Chulan Zhan, Tong Lin, Yangzhi Qiu, Honglang Zhang, Xiaohong Xie, Xinqin Lin, Ming Liu, Liqiang Wang, Chengzhi Zhou

Publikováno v: The Clinical Respiratory Journal, Vol 18, Iss 8, Pp n/a-n/a (2024)

ABSTRACT Background Young lung cancer is a rare subgroup accounting for 5% of lung cancer. The aim of this study was to compare the causes of death (COD) among lung cancer patients of different age groups and construct a nomogram to predict cancer‐

Externí odkaz: https://doaj.org/article/c7b31f11b8ee498e9574f4d594e85ff6

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib

Autor: Yongfeng Yu, Wen Dong, Yanxia Shi, Rong Wu, Qitao Yu, Feng Ye, Chengzhi Zhou, Xiaorong Dong, Xingya Li, Yongsheng Li, Zhen Li, Lin Wu, Yueyin Pan, Hong Shen, Dehua Wu, Zhongyuan Xu, Jinsheng Wu, Nong Xu, Yanru Qin, Aimin Zang, Jingdong Zhang, Jianya Zhou, Xiaotao Zhang, Yanqiu Zhao, Fugen Li, Huizhen Wang, Qi Liu, Zhenyong Han, Jin Li, Shun Lu

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 16 (2024)

Background: MET overexpression represents the most MET aberration in advanced non-small-cell lung cancer (NSCLC). However, except MET exon 14 ( MET ex14) skipping mutation was recognized as a clinical biomarker, the role of MET overexpression as a pr

Externí odkaz: https://doaj.org/article/8250df8367a343a395e6e10c30dba4a2